Studies have shown aggressive cancer care at the end of life is associated with decreased quality of life, decreased median survival, and increased cost of care. This study describes the patients most likely to receive systemic anticancer therapy at the end of life in a community cancer institute.
Materials and Methods:
We performed a retrospective cohort study of 201 patients who received systemic anticancer therapy in our institution and died between July 2016 and April 2017. Data collected included primary malignancy, hospice enrollment, healthcare utilization, Oncology Care Model (OCM) enrollment, and clinical assessments at last office visit prior to a treatment decision before death. We defined our outcome variable as the receipt of anticancer treatment in the last 14 days of a patient’s life. We evaluated 20 clinical exposure variables with respect to the outcome classes. Risk ratios along with their associated confidence intervals and P values were calculated. Significance was determined using the Benjamini-Hochberg procedure to account for multiple testing.
Results:
Of the 201 patients who died of cancer, 36 (17%) received anticancer therapy within the last 14 days of life. Several risk factors were significantly positively associated with receiving anticancer therapy at the end of life including hospitalization within 30 days of end of life, number of hospitalizations per patient (≥2), death in hospital, enrollment in OCM, and a diagnosis of hematologic malignancy.
Conclusion:
Our findings demonstrate those enrolled in the OCM and those with hematologic malignancies have a higher risk of receiving anticancer therapy in the last 14 days of life. These observations highlight the need for better identifying the needs of high-risk patients and providing good quality care throughout the disease trajectory to better align end-of-life care with patients’ wishes.
McCarthyM.Chemotherapy does not improve quality of life in cancer patients at end of life, US study finds. BMJ. 2015;351:h4139.
2.
EarleCCNevilleBALandrumMB, et al.Evaluating claims-based indicators of the intensity of end-of-life cancer care. Int J Qual Health Care. 2005;17(6):505–509.
3.
American Society of Clinical Oncology. Quality Oncology Practice Initiative (QOPI®). Quality Measures. http://qopi.asco.org/. Accessed May 24, 2019.
4.
EarleCCNevilleBALandrumMBAyanianJZBlockSDWeeksJC. Trends in the aggressiveness of cancer care near the end of life. J Clin Oncol. 2004;22(2):315–321.
5.
BarberaLPaszatLChartierC. Indicators of poor quality end-of-life cancer care in Ontario. J Palliat Care. 2006;22(1):12–17.
6.
AdamHHugSBosshardG. Chemotherapy near the end of life: a retrospective single-centre analysis of patients’ charts. BMC Palliat Care. 2014;13:26.
7.
BragaSMirandaAFonsecaR, et al.The aggressiveness of cancer care in the last three months of life: a retrospective single centre analysis. Psychooncology. 2007;16(9):863–868.
BenjaminiYHochbergY. Controlling the false discovery rate: a practical and powerful, approach to multiple testing. J R Stat Soc Series B (Methodological). 1995;57(1):289–300.
10.
NiederCTollaliTDalhaugA, et al.Active anticancer treatment during the final month of life in patients with non-small cell lung cancer. Anticancer Res. 2014;34(2):1015–1020.
11.
HoTHBarberaLSaskinRLuHNevilleBAEarleCC. Trends in the aggressiveness of end-of-life cancer care in the universal health care system of Ontario, Canada. J Clin Oncol. 2011;29(12):1587–1591.
12.
Taberner BonastrePTaberner BonastreMTSoler CompanyEPerez-Serrano LainosaMD. Chemotherapy near the end of life; assessment of the clinical practise in onco-hematological in adult patients. Farm Hosp. 2016;40(1):14–24.
13.
TemelJSMcCannonJGreerJA, et al.Aggressiveness of care in a prospective cohort of patients with advanced NSCLC. Cancer. 2008;113(4):826–833.
14.
ShengJZhangYXHeXB, et al.Chemotherapy near the end of life for Chinese patients with solid malignancies. Oncologist. 2017;22(1):53–60.
15.
WangSYHallJPollackCE, et al.Trends in end-of-life cancer care in the Medicare program. J Geriatr Oncol. 2016;7(2):116–125.
16.
EarleCCParkERLaiBWeeksJCAyanianJZBlockS. Identifying potential indicators of the quality of end-of-life cancer care from administrative data. J Clin Oncol. 2003;21(6):1133–1138.
17.
TemelJSGreerJAAdmaneS, et al.Longitudinal perceptions of prognosis and goals of therapy in patients with metastatic non-small-cell lung cancer: results of a randomized study of early palliative care. J Clin Oncol. 2011;29(17):2319–2326.
18.
FriedTRBradleyEHTowleVRAlloreH. Understanding the treatment preferences of seriously ill patients. N Engl J Med. 2002;346(14):1061–1066.
19.
RoseJHO’TooleEEDawsonNV, et al.Perspectives, preferences, care practices, and outcomes among older and middle-aged patients with late-stage cancer. J Clin Oncol. 2004;22(24):4907–4917.
20.
WeeksJCCookEFO’DaySJ, et al.Relationship between cancer patients’ predictions of prognosis and their treatment preferences. JAMA. 1998;279(21):1709–1714.
21.
Brinkman-StoppelenburgARietjensJAvan der HeideA. The effects of advance care planning on end-of-life care: a systematic review. Palliat Med. 2014;28(8):1000–1025.
22.
MackJWCroninAKeatingNL, et al.Associations between end-of-life discussion characteristics and care received near death: a prospective cohort study. J Clin Oncol. 2012;30(35):4387–4395.
23.
LennesITTemelJSHoedtCMeilleurALamontEB. Predictors of newly diagnosed cancer patients’ understanding of the goals of their care at initiation of chemotherapy. Cancer. 2013;119(3):691–699.
24.
LubitzJDRileyGF. Trends in Medicare payments in the last year of life. N Engl J Med. 1993;328(15):1092–1096.
25.
RileyGFLubitzJD. Long-term trends in Medicare payments in the last year of life. Health Serv Res. 2010;45(2):565–576.
26.
CollaCHMordenNESkinnerJSHovermanJRMearaE. Impact of payment reform on chemotherapy at the end of life. J Oncol Pract. 2012;8(suppl 3):e6s–e13s.
27.
McCarthyEPBurnsRBNgo-MetzgerQDavisRBPhillipsRS. Hospice use among Medicare managed care and fee-for-service patients dying with cancer. JAMA. 2003;289(17):2238–2245.
28.
SpainPWestNTeixeira-PoitSSchaeferEKetlerK. Oncology Care Model: Early palliative care experiences and outcomes. J Clin Oncol. 2017;35(suppl 31):37. doi:10.1200/JCO.2017.35.31_suppl.37.
29.
HowellDAShellensRRomanEGarryACPatmoreRHowardMR. Haematological malignancy: are patients appropriately referred for specialist palliative and hospice care? A systematic review and meta-analysis of published data. Palliat Med. 2011;25(6):630–641.
30.
HuiDDidwaniyaNVidalM, et al.Quality of end-of-life care in patients with hematologic malignancies: a retrospective cohort study. Cancer. 2014;120(10):1572–1578.
31.
ManittaVJPhilipJACole-SinclairMF. Palliative care and the hemato-oncological patient: can we live together? A review of the literature. J Palliat Med. 2010;13(8):1021–1025.
32.
FreemanATWoodWAFoxAHansonLC. Access to palliative care consultation and advance care planning for adults with high-risk Leukemia. J Palliat Med. 2018;21(2):225–228.
33.
BoucherNAJohnsonKSLeBlancTW. Acute leukemia patients’ needs: qualitative findings and opportunities for early palliative care. J Pain Symptom Manage. 2018;55(2):433–439.
34.
ManittaVZordanRCole-SinclairMNandurkarHPhilipJ. The symptom burden of patients with hematological malignancy: a cross-sectional observational study. J Pain Symptom Manage. 2011;42(3):432–442.
35.
FadulNAEl OstaBDalalSPoulterVABrueraE. Comparison of symptom burden among patients referred to palliative care with hematologic malignancies versus those with solid tumors. J Palliat Med. 2008;11(3):422–427.
36.
LeBlancTWRitchieCSFriedmanF, et al.Adherence to measuring what matters items when caring for patients with hematologic malignancies versus solid tumors. J Pain Symptom Manage. 2016;52(6):775–782.
37.
OdejideOOSalas CoronadoDYWattsCDWrightAAAbelGA. End-of-life care for blood cancers: a series of focus groups with hematologic oncologists. J Oncol Pract. 2014;10(6):e396–403.
38.
LeBlancTWAbernethyAPCasarettDJ. What is different about patients with hematologic malignancies? A retrospective cohort study of cancer patients referred to a hospice research network. J Pain Symptom Manage. 2015;49(3):505–512.
39.
SexauerAChengMJKnightLRileyAWKingLSmithTJ. Patterns of hospice use in patients dying from hematologic malignancies. J Palliat Med. 2014;17(2):195–199.
40.
El-JawahriANelson-LoweMVanDusenH, et al.Patient-clinician discordance in perceptions of treatment risks and benefits in older patients with acute myeloid leukemia. Oncologist. 2019;24(2):247–254.
41.
Porta-SalesJGuerrero-TorrellesMMoreno-AlonsoD, et al.Is early palliative care feasible in patients with multiple myeloma?J Pain Symptom Manage. 2017;54(5):692–700.
42.
El-JawahriALeBlancTVanDusenH, et al.Effect of inpatient palliative care on quality of life 2 weeks after hematopoietic stem cell transplantation: a randomized clinical trial. JAMA. 2016;316(20):2094–2103.
43.
EinavLFinkelsteinAMullainathanSObermeyerZ. Predictive modeling of U.S. health care spending in late life. Science. 2018;360(6396):1462–1465.
